Allegro Ophthalmics and Senju Pharmaceutical Announce Collaboration in Japan to Develop Integrin Peptide Therapy as First in

  Allegro Ophthalmics and Senju Pharmaceutical Announce Collaboration in Japan
  to Develop Integrin Peptide Therapy as First in-Class Treatment of Vascular
  Eye Diseases

Business Wire

SAN JUAN CAPISTRANO, Calif. & OSAKA, Japan -- May 2, 2013

Allegro Ophthalmics, LLC and Senju Pharmaceutical Co., Ltd. today announced
that they have entered into a collaboration and license agreement to develop
and market Allegro’s Integrin Peptide Therapy in Japan. With this
collaboration, Allegro and Senju aim to improve the quality of life for
patients worldwide who continue to be at risk of blindness from vascular eye
diseases by establishing Integrin Peptide Therapy as the first-in-class
treatment targeting integrin with an oligopeptide.

Under the terms of the agreement, Senju will acquire the rights to co-develop
and market Allegro’s Integrin Peptide Therapy in Japan as an intravitreal
injection for vascular eye diseases such as wet age-related macular
degeneration (AMD) and diabetic macular edema (DME). In exchange for these
rights, Senju has agreed to pay Allegro an eight-digit upfront license fee,
additional development and sales milestone fees, and a percentage royalty on
net sales.

“Allegro is very pleased to have formed this strategic partnership with one of
the leading ophthalmic pharmaceutical companies in Japan,” said Marc
Kirshbaum, Chief Operating Officer, Allegro Ophthalmics. “In addition to
validating the potential of Integrin Peptide Therapy as an additional
treatment option for millions of patients at risk of blindness, this
partnership provides Allegro with the capital required to significantly
progress its clinical program across multiple indications and phases in the
United States.”

Senju had a similarly positive outlook on the relationship. “The announcement
of this partnership with Allegro further evidences Senju’s commitment to its
position as a leader in ophthalmology in Japan,” said Shuhei Yoshida,
Executive Vice President of Senju Pharmaceutical. “We believe that Allegro’s
Integrin Peptide Therapy shows great promise as a first-in-class treatment for
Wet AMD, DME, and other vascular eye indications, and we are eager to begin
the process for regulatory approval in Japan.”

Summit Pharmaceuticals International, a subsidiary of Sumitomo Corporation,
served as advisor to Allegro in connection with this transaction.

Allegro recently announced that it completed enrollment of a Phase Ib/IIa
study in Wet AMD patients as stand-alone therapy, and commencement of a Phase
Ib/IIa in combination with anti-VEGF therapy. These two human studies are in
addition to a previous Phase I study in end-stage DME patients. All data from
human studies, as well as studies in animals, show Integrin Peptide Therapy to
be safe, well-tolerated and efficacious, including the fact that the benefit
of mono-therapy is holding at least three months off-treatment in both Wet AMD
and DME patients.

About Integrin Peptide Therapy

Integrin Peptide Therapy, a novel approach to treating vascular eye diseases,
utilizes an oligopeptide discovered by Allegro’s founders in collaboration
with Caltech. Integrin Peptide Therapy uniquely approaches multiple
indications by collectively turning off the production of aberrant blood
vessels, reducing the leakage of aberrant blood vessels, and inhibiting the
growth of aberrant blood vessels. This novel approach has the potential to be
both an effective stand-alone treatment as well as complementary to existing
standard of care due to its unique mechanism of action.

To learn more about Allegro and Integrin Peptide Therapy, please visit or contact Allegro’s Chief Operating Officer, Marc
Kirshbaum, at

About Allegro Ophthalmics, LLC

With more than 100 years of combined experience in vision science and
medicine, the leadership team at Allegro Ophthalmics, LLC is establishing
Integrin Peptide Therapy as the next-generationpharmaceutical category for
the treatment of wet age-related macular degeneration, diabetic retinopathy
and diabetic macular edema, which together affect nearly six million
Americans. Allegro Ophthalmics seeks to prevent vision loss and
combatblindness, potentially offering millions an improved quality of life
sustained by self-sufficient, functional vision.

About Senju Pharmaceutical Co., Ltd.

Established in 1947 and headquartered in Osaka, Japan, Senju Pharmaceutical
Co., Ltd., is a company that develops, manufactures, and commercializes a
variety of innovative products on a global basis, specializing in ophthalmic


Pascale Communications, LLC
Allison Potter, 619-550-1867
Press spacebar to pause and continue. Press esc to stop.